Atypical femoral fractures bilaterally in a patient receiving denosumab

Acta Orthop. 2014 Feb;85(1):3-5. doi: 10.3109/17453674.2013.854668. Epub 2013 Oct 31.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Alendronate / adverse effects
  • Alendronate / therapeutic use
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bone Density Conservation Agents / administration & dosage
  • Bone Density Conservation Agents / adverse effects*
  • Bone Density Conservation Agents / therapeutic use
  • Denosumab
  • Drug Administration Schedule
  • Female
  • Femoral Fractures / chemically induced*
  • Femoral Fractures / diagnostic imaging
  • Fractures, Stress / chemically induced*
  • Fractures, Stress / diagnostic imaging
  • Humans
  • Osteoporosis, Postmenopausal / drug therapy
  • Osteoporotic Fractures / prevention & control
  • Radiography

Substances

  • Antibodies, Monoclonal, Humanized
  • Bone Density Conservation Agents
  • Denosumab
  • Alendronate